Thinly traded micro cap Auris Medical Holdings (EARS +19%) heads north on a 6x surge in volume. No particular news accounts for the move, but top-line results from a Phase 3 study assessing lead product candidate AM-101 for the treatment of acute tinnitus (ringing in the ear) are expected this month.
AM-101 contains esketamine hydrochloride, an N-Methyl-D-aspartate (NMDA) receptor antagonist. It is administered in one treatment cycle consisting of three injections into the middle ear over three to five days. Once injected, the drug diffuses through the round window into the cochlea.
Subscribe for full text news in your inbox